GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Customize this Report

Most Exhaustive Report

70 Pages

Bruton's tyrosine kinase (Btk) is a member of the Tec family of cytoplasmic protein tyrosine kinases (PTK). BTK enzyme  is encoded by the BTK gene. It is expressed in the cells of all hematopoietic lineages except for T and plasma cells. The protein kinase BTK is implicated in the development, differentiation, and activation of B cells through its role in the BCR and TLR signaling cascades. Clinical evidence indicates loss-of-function mutations in BTK result in X-linked agammaglobulinemia and cancers. Thus BTK has emerged as a novel anticancer target for the treatment of B-cell lymphomas and leukemias.

Currently, marketed anti-BTK drug is Imbruvica (ibrutinib). It is indicated for the treatment of graft versus host disease, hematological malignancies, and Non-Hodgkin’s lymphoma.

Pipeline activity of BTK inhibitors is quite dynamic. Several BTK inhibitors candidates more than 20 are in late stage clinical trials and are expected to achieve the regulatory approval in the near future which includes GDC-0834, GDC-0834, RN486, TP-4207, PCI-45261, BGB-3111, PCI 45292, ABBV-105, PRN1008, HCI-1401, EBI-1367, EBI-1266, SNS-062, RG7845, and GDC-0853. Preclinical and early clinical results indicate that these inhibitors are useful for the treatment of lymphomas and leukemias. The companies which are involved in the development of BTK inhibitors are Gilead, Roche, AbbVie, J&J, Eli Lilly, AstraZeneca, and Biogen.

Reasons to Buy

  • To gain erudite insights about the Bruton's tyrosine kinase (BTK) inhibitors pipeline landscape
  • To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
  • To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
  • To identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right partners for strategic collaborations
  • To obtain informed updates on drug termination/drug discontinuation

 

Read More

Select a license type that suits your business needs

Single User Licence
$1500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$2000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$3000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

Our Clients

Related Reports

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date